ROCK SPRINGS CAPITAL MANAGEMENT LP
Q1 2026 Form 13-F
BALTIMORE, MARYLAND
CIK 0001595725
· CRD 168648
· SEC-registered investment adviser
$1.7B Reported Value Total
ROCK SPRINGS CAPITAL reports 6 total accounts under management (AUM). There are 6 discretionary accounts valued at $2,426,287,072, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
Private funds (Form ADV)
2 funds
· $2.4B gross asset value
Hedge Fund: $2.4B
Source: Form ADV filed 2026-03-24
Reported value
$1.7B
Quarter over quarter
-5.1%
Holdings
100
Top-10 concentration
40.6%
Key People
Form ADV owners & control persons
Gordon Margraf ("mark") Bussard
MEMBER/LIMITED PARTNER
Kris Harlan Jenner
MEMBER/LIMITED PARTNER
Nnamdi C Etoh
CHIEF FINANCIAL OFFICER
Filing Navigation
13F Metrics
Loading 13F Metrics
Q1 2026 13F record
Q1 2026 13F filing summary
| Period of report | March 31, 2026 |
|---|---|
| Filed | May 15, 2026 |
| Form | 13F-HR |
| Reported value | $1.7B |
| Positions | 100 |
| Change in reported value | -13.0% |
| New positions | 11 |
| Exited positions | 9 |
| Position turnover | 18.4% |
| Top-10 concentration | 40.6% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q2 2026 13F
Filed Aug 14, 2026
|
104 | $2.0B |
|
Q1 2026 13F
Filed May 15, 2026
|
100 | $1.7B |
|
Q4 2025 13F
Filed Feb 17, 2026
|
97 | $2.0B |
|
Q3 2025 13F
Filed Nov 14, 2025
|
91 | $1.7B |
|
Q2 2025 13F
Filed Aug 14, 2025
|
92 | $1.6B |
|
Q1 2025 13F
Filed May 15, 2025
|
95 | $1.7B |
|
Q4 2024 13F
Filed Feb 14, 2025
|
105 | $2.6B |
|
Q3 2024 13F
Filed Nov 14, 2024
|
107 | $3.1B |
|
Q2 2024 13F
Filed Aug 14, 2024
|
107 | $3.3B |
|
Q1 2024 13F
Filed May 15, 2024
|
109 | $3.9B |
|
Q4 2023 13F
Filed Feb 14, 2024
|
99 | $4.1B |
|
Q3 2023 13F
Filed Nov 14, 2023
|
116 | $3.7B |
|
Q2 2023 13F
Filed Aug 14, 2023
|
119 | $4.2B |
|
Q1 2023 13F
Filed May 15, 2023
|
116 | $4.2B |
|
Q4 2022 13F
Filed Feb 14, 2023
|
116 | $4.2B |
|
Q3 2022 13F
Filed Nov 14, 2022
|
123 | $3.9B |
|
Q2 2022 13F
Filed Aug 15, 2022
|
125 | $3.4B |
|
Q1 2022 13F
Filed May 16, 2022
|
128 | $4.0B |
|
Q4 2021 13F
Filed Feb 14, 2022
|
128 | $4.3B |
|
Q3 2021 13F
Filed Nov 15, 2021
|
145 | $4.8B |
31 earlier quarters on file — choose one from the quarter menu above.
Top 20 holdings · Q1 2026
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | RVMD REVOLUTION MEDICINES INC | $117.6M | 6.93% |
| 2 | LLY ELI LILLY & CO | $90.8M | 5.35% |
| 3 | MDGL MADRIGAL PHARMACEUTICALS INC | $89.5M | 5.28% |
| 4 | MIRM MIRUM PHARMACEUTICALS INC | $74.9M | 4.42% |
| 5 | ARGX ARGENX SE | $71.9M | 4.24% |
| 6 | RYTM RHYTHM PHARMACEUTICALS INC | $60.0M | 3.54% |
| 7 | INSM INSMED INC | $51.4M | 3.03% |
| 8 | ASND ASCENDIS PHARMA A/S | $44.4M | 2.62% |
| 9 | XENE XENON PHARMACEUTICALS INC | $44.4M | 2.62% |
| 10 | TVTX TRAVERE THERAPEUTICS INC | $43.9M | 2.59% |
| 11 | KYMR KYMERA THERAPEUTICS INC | $41.4M | 2.44% |
| 12 | PEN PENUMBRA INC | $39.6M | 2.33% |
| 13 | ISRG INTUITIVE SURGICAL INC | $37.8M | 2.23% |
| 14 | SRRK SCHOLAR ROCK HLDG CORP | $36.4M | 2.14% |
| 15 | ELVN ENLIVEN THERAPEUTICS INC | $32.4M | 1.91% |
| 16 | BSX BOSTON SCIENTIFIC CORP | $32.3M | 1.91% |
| 17 | IRTC IRHYTHM HOLDINGS INC | $30.9M | 1.82% |
| 18 | GPCR STRUCTURE THERAPEUTICS INC | $30.9M | 1.82% |
| 19 | AGIO AGIOS PHARMACEUTICALS INC | $27.0M | 1.59% |
| 20 | RARE ULTRAGENYX PHARMACEUTICAL IN | $25.5M | 1.5% |
Values as reported on the Q1 2026 Form 13F. Every position is in the holdings table below.